




RealRate

# PHARMACEUTICAL 2019

Ocuphire Pharma Inc.  
Rank 232 of 363





# PHARMACEUTICAL 2019

Ocuphire Pharma Inc.  
Rank 232 of 363



The relative strengths and weaknesses of Ocuphire Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ocuphire Pharma Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 71% points. The greatest weakness of Ocuphire Pharma Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 76% points.

The company's Economic Capital Ratio, given in the ranking table, is 35%, being 1.5% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	15,900
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	0
Liabilities, Non-Current	0
Other Assets	31
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	5,480
Other Net Income	6,169
Other Revenues	0
Property and Equipment	112
Research and Development	13,109
Selling, General and Administrative Expense	7,429

Output Variable	Value in 1000 USD
Assets	16,043
Liabilities	5,480
Expenses	20,538
Revenues	0
Stockholders Equity	10,563
Net Income	-14,369
Comprehensive Net Income	-14,369
Economic Capital Ratio	35%